Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Outstanding (Diluted Average) (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $57.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 7.39% to $57.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.9 million through Dec 2025, up 7.39% year-over-year, with the annual reading at $57.9 million for FY2025, 7.39% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $57.9 million at 4D Molecular Therapeutics, up from $55.9 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $57.9 million in Q4 2025, with the low at $26.7 million in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $42.1 million, with a median of $39.1 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) surged 50.57% in 2024, then rose 0.68% in 2025.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $27.7 million in 2021, then grew by 16.66% to $32.4 million in 2022, then grew by 20.95% to $39.1 million in 2023, then surged by 37.86% to $53.9 million in 2024, then increased by 7.39% to $57.9 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $57.9 million, $55.9 million, and $55.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.